Types of Research
- (-) Remove Market & Value Chain Analysis filter Market & Value Chain Analysis
- (-) Remove Literature Review filter Literature Review
- (-) Remove Health filter Health
- (-) Remove 2018 filter 2018
- (-) Remove 2020 filter 2020
Recent research has used typologies to classify rural households into categories such as “subsistence” versus “commercialized” as a means of targeting agricultural development interventions and tracking agricultural transformation. Following an approach proposed by Alliance for a Green Revolution in Africa, we examine patterns in two agricultural transformation hallmarks – commercialization of farm output, and diversification into non-farm income – among rural households in Ethiopia, Nigeria, and Tanzania from 2008-2015. We classify households into five smallholder farm categories based on commercialization and non-farm income levels (Subsistence, Pre-commercial, Transitioning, Specialized Commercial, and Diversified Commercial farms), as well as two non-smallholder categories (Largeholder farms and Non-farm households). We then summarize the share of households in each of these categories, examine geographic and demographic factors associated with different categories, and explore households’ movement across categories over time. We find a large amount of “churn” across categories, with most households moving to a different (more or less commercialized, more or less diversified) category across survey years. We also find many non-farm households become smallholder farmers – and vice versa – over time. Finally, we show that in many cases increases in farm household commercialization or diversification rates actually reflect decreased total farm production, or decreased total income (i.e., declines in the denominators of the agricultural transformation metrics), suggesting a potential loss of rural household welfare even in the presence of “positive” trends in transformation indicators. Findings underscore challenges with using common macro-level indicators to target development efforts and track progress at the household level in rural agrarian communities.
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.